“We are looking at this with great care and examining all of the evidence that is out there,” Britain’s security minister James Brokenshire told Sky News.
Related Articles
Reading Rheum
Handpicked Reviews of Contemporary Literature
Should Hydroxychloroquine Level Testing Be Standard Care in Lupus?
The Johns Hopkins Lupus Center, Baltimore, has described its experience using hydroxychloroquine (HCQ) levels.1 Forty-four percent of its patients had levels below 500 ng/mL (partial nonadherence); 13% were severely nonadherent (<200 ng/mL). They were shown their results and educated on HCQ adherence. Adherence then improved to 80%; those with lower HCQ levels had higher disease…
Rheumatologists Debate Hydroxychloroquine Dosing Guidelines for Lupus
CHICAGO—The correct dosing of hydroxychloroquine (HCQ) for systemic lupus erythematosus (SLE) is a concern of all rheumatologists. Petros Efthimiou, MD, clinical professor of medicine at New York University, New York City, opened the Great Debate of the 2018 ACR/ARHP Annual Meeting by stating, “Today, we will be discussing a critical clinical problem that affects everyone’s…
Old Drug, New Interest: COVID-19 Spurs Hydroxychloroquine Supply Concerns for Rheumatic Disease Patients
After a study investigated if hydroxycholoroquine (HCQ) benefits COVID-19 patients, the drug—used to treat SLE and RA patients—began running out in pharmacies around the U.S. ACR leaders have asked the FDA to increase monitoring of the HCQ supply…